Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients

被引:0
|
作者
C C Barker
J D Butzner
R A Anderson
R Brant
R S Sauve
机构
[1] University of British Columbia,Department of Pediatrics
[2] University of Calgary,Department of Pediatrics
[3] University of Calgary,Department of Oncology
[4] University of Calgary,Department of Community Health Sciences
来源
Bone Marrow Transplantation | 2003年 / 32卷
关键词
hematopoietic stem cell transplantation; veno-occlusive disease; pediatric; risk factor; survival;
D O I
暂无
中图分类号
学科分类号
摘要
The incidence, risk factors and mortality of veno-occlusive disease (VOD) were identified for 142 pediatric hematopoietic stem cell (HSC) transplant recipients with hematological malignancies (83), solid tumors (41) and nonmalignant diseases (18). This historical cohort of 142 HSC transplant patients, from January 1993 through June 2000, was assessed by chart review. Risk factors for the development of VOD and mortality were assessed by multiple logistic regression and Kaplan–Meier survival curves respectively. The incidence of VOD was 18.3% (26/142 transplants). Multivariate analysis reconfirmed the known pretransplant risk factors of induction therapy with busulfan and transplantation with matched unrelated donor cells as significant risk factors for the development of VOD. In addition, two new risk factors, positive CMV serology in the recipient and TPN provided in the 30 days prior to transplant, were identified. Mortality in transplant patients at 100 days was greater in the VOD-positive group (10/26 (38.5%)) compared to the VOD-negative group (11/116 (9.5%) (P=0.001)). The risk of death was 4.97 times higher with 95% CIs (2.11, 11.71) for the VOD-positive group. Decreasing the risk factors for VOD may decrease mortality in this patient population.
引用
收藏
页码:79 / 87
页数:8
相关论文
共 50 条
  • [21] Prognostic Factors Associated With Increased Mortality in Pediatric Veno-Occlusive Disease Following Hematopoietic Cell Transplantation
    Zaidman, Irina
    Barsoum, Natalie
    Even-Or, Ehud
    Daher, Miriam
    Aran, Adi Avniel
    Stepensky, Polina
    Gefen, Aharon
    CLINICAL TRANSPLANTATION, 2024, 38 (12)
  • [22] Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population?
    Szmit, Zofia
    Gorczynska, Ewa
    Mielcarek-Siedziuk, Monika
    Ussowicz, Marek
    Owoc-Lempach, Joanna
    Kalwak, Krzysztof
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (03): : 339 - 344
  • [23] Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease
    Eber, S. W.
    Gungor, T.
    Veldman, A.
    Sykora, K.
    Scherer, F.
    Fischer, D.
    Grigull, L.
    PEDIATRIC TRANSPLANTATION, 2007, 11 (01) : 49 - 57
  • [24] Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population
    Sartori, MT
    Spiezia, L
    Cesaro, S
    Messina, C
    Paris, M
    Pillon, M
    Saggiorato, G
    Pagnan, A
    Girolami, A
    Zanesco, L
    Cella, G
    THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) : 682 - 689
  • [25] A Second Look: Retrospective Identification of Thrombotic Microangiopathy in Pediatric Stem Cell Transplant Patients With Veno-Occlusive Disease
    Rahim, Mahvish Q.
    Nichols, Cydney
    Althouse, Sandra
    Rahrig, April L.
    PEDIATRIC TRANSPLANTATION, 2025, 29 (01)
  • [26] Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation
    Shin, Seung-Hwan
    Yahng, Seung-Ah
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Kim, Yoo-Jin
    BLOOD RESEARCH, 2013, 48 (01) : 55 - 57
  • [27] Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin
    Ladha, Abdullah
    Mannis, Gabriel
    Muffly, Lori
    LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 257 - 263
  • [28] Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review
    Zhang, Lifei
    Wang, Yebo
    Huang, He
    CLINICAL TRANSPLANTATION, 2012, 26 (04) : 511 - 519
  • [29] Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies
    Daniel KL Cheuk
    World Journal of Transplantation, 2012, (02) : 27 - 34
  • [30] Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation
    Corbacioglu, Selim
    Kernan, Nancy
    Lehmann, Leslie
    Brochstein, Joel
    Revta, Carolyn
    Grupp, Stephan
    Martin, Paul
    Richardson, Paul G.
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (03) : 291 - 302